Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study.
EClinicalMedicine. 2022 Jul 1;51:101542. doi: 10.1016/j.eclinm.2022.101542. eCollection 2022 Sep.
EClinicalMedicine. 2022.
PMID: 35795398
Free PMC article.
Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study.
García-Pérez J, González-Pérez M, Castillo de la Osa M, Borobia AM, Castaño L, Bertrán MJ, Campins M, Portolés A, Lora D, Bermejo M, Conde P, Hernández-Gutierrez L, Carcas A, Arana-Arri E, Tortajada M, Fuentes I, Ascaso A, García-Morales MT, Erick de la Torre-Tarazona H, Arribas JR, Imaz-Ayo N, Mellado-Pau E, Agustí A, Pérez-Ingidua C, Gómez de la Cámara A, Ochando J, Belda-Iniesta C, Frías J, Alcamí J, Pérez-Olmeda M; CombiVacS study Group.
García-Pérez J, et al. Among authors: castillo de la osa m.
EClinicalMedicine. 2022 Jul 1;50:101529. doi: 10.1016/j.eclinm.2022.101529. eCollection 2022 Aug.
EClinicalMedicine. 2022.
PMID: 35795713
Free PMC article.
Item in Clipboard
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.
Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, Campins M, Portolés A, González-Pérez M, García Morales MT, Arana-Arri E, Aldea M, Díez-Fuertes F, Fuentes I, Ascaso A, Lora D, Imaz-Ayo N, Barón-Mira LE, Agustí A, Pérez-Ingidua C, Gómez de la Cámara A, Arribas JR, Ochando J, Alcamí J, Belda-Iniesta C, Frías J; CombiVacS Study Group.
Borobia AM, et al.
Lancet. 2021 Jul 10;398(10295):121-130. doi: 10.1016/S0140-6736(21)01420-3. Epub 2021 Jun 25.
Lancet. 2021.
PMID: 34181880
Free PMC article.
Clinical Trial.
Item in Clipboard
Impaired Antibody-Dependent Cellular Cytotoxicity in a Spanish Cohort of Patients With COVID-19 Admitted to the ICU.
Vigón L, García-Pérez J, Rodríguez-Mora S, Torres M, Mateos E, Castillo de la Osa M, Cervero M, Malo De Molina R, Navarro C, Murciano-Antón MA, García-Gutiérrez V, Planelles V, Alcamí J, Pérez-Olmeda M, Coiras M, López-Huertas MR.
Vigón L, et al. Among authors: castillo de la osa m.
Front Immunol. 2021 Sep 20;12:742631. doi: 10.3389/fimmu.2021.742631. eCollection 2021.
Front Immunol. 2021.
PMID: 34616404
Free PMC article.
Item in Clipboard
Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern.
García-Pérez J, Bermejo M, Ramírez-García A, De La Torre-Tarazona HE, Cascajero A, Castillo de la Osa M, Jiménez P, Aparicio Gómez M, Calonge E, Sancho-López A, Payares-Herrera C, Layunta Acero R, Vicente-Izquierdo L, Avendaño-Solá C, Alcamí J, Pérez-Olmeda M, Díez-Fuertes F.
García-Pérez J, et al. Among authors: castillo de la osa m.
J Med Virol. 2023 Mar;95(3):e28679. doi: 10.1002/jmv.28679.
J Med Virol. 2023.
PMID: 36929737
Item in Clipboard
Cite
Cite